Today, on the first trading day of 2026, Stocks Down Under publishes its its 10 Hottest ASX Stocks to Look At in the year ahead!
What are the Best ASX Stocks to invest in right now?
Check our buy/sell tips
[sg_popup id="23914" event="click"][/sg_popup]
Stocks Down Under's Top 10 Hottest ASX Stocks to Look At in 2026!
Note: These…
IPOs
This article outlines 5 ASX Predictions for 2026 that Stocks Down Under puts its neck on the line to assert will happen. It has become an annual tradition of ours, and some of these calls we get right, others we don't. Arguably our boldest call in suggesting ANZ would be the best performing big 4…
Saluda Medical (ASX:SLD) listed on Friday after raising AU$230 million at AU$2.65 per share, marking a rare bright spot in an otherwise quiet year for ASX biotech debuts. Unlike most life sciences IPOs that arrive with little more than clinical-stage promise, Saluda Medical already generates US$70 million in annual revenue and is targeting US$82 million…
Hear the term 'Activist investors' and you might think of GetUp, the progressive activist group that forced Woolworths to hold an EGM in 2014 in an attempt to limit the maximum bets on poker machines to $1. Or perhaps even of ESG-focused fundies like Australian Ethical (ASX:AEF). The reality is a lot more complicated and…
After an explosive market debut that saw its share price surge more than 40% on day one, Greatland Resources (ASX: GGP) has since fallen sharply—dropping 24% following a major downgrade to its gold production guidance. For investors, the shift was striking. One moment the market was celebrating a high-profile acquisition from Newmont and ambitious production…
On 31 July 2025, the company listed its shares at US$33. By the end of the day, the price had surged to around US$115.50, marking a gain of approximately 230%. That sharp rise pushed Figma’s value from US$19.3 billion to almost US$67.6 billion in a single trading session.
For a design software company, that’s a big…
ASX Reporting Season is almost upon us once again. It is the most important time of the year for investors, a time many reconsider if their thesis still holds, many choose to buy into a stock or sell, some will receive dividends (either expectedly or unexpectedly) whilst others will be disappointed. While you may not…
Is it possible at all to time the market? Some will tell you it is possible, but they were probably just lucky and/or were not even trying to. Others will tell you it is not possible, but they are most likely trying to find an excuse to blame poor short-term performance.
Let's take a serious look…
Have you ever heard the term Dogs of the ASX? It can either allude to the worst stocks in the ASX generally, or perhaps the investment strategy of buying these worst performing shares at the start of a new year (either a calendar or financial year), thinking they will rebound.
Many will be considering this strategy,…
After two slow years marked by rising interest rates and cautious markets, 2025 looks set to be a turning point for ASX IPOs. However, this isn’t simply a broad rebound. What we’re seeing is a more selective and strategic shift. Companies coming to market now are picking their moment carefully, looking to list in the…
